Impact of Using Corticosteroid Prophylaxis to Prevent Tumor Flare Reactions During 177Lu-DOTATATE Treatment in Patients with Neuroendocrine Tumors
Short-course corticosteroid prophylaxis to prevent tumor flare reactions in high-risk patients with neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE did not appear to decrease the incidence of tumor flare reactions compared to previously reported numbers. Randomized, placebo-controlled trials looking at the use of corticosteroids to prevent tumor flare reactions in patients treated with <sup>177</sup>Lu-DOTATATE are needed to fully elucidate the safety and efficacy of corticosteroids used in this setting and to determine the impact on treatment outcomes.
Authors
- Emily Skotte
- Robert A. Ramirez (ORCID: https://orcid.org/0000-0001-8762-5852)
- Shannon Stockton (ORCID: https://orcid.org/0000-0003-2799-663X)
- Amanda S. Cass (ORCID: https://orcid.org/0000-0003-1761-4642)
- Margaret Wheless (ORCID: https://orcid.org/0000-0002-4494-1350)
Institutions
- Vanderbilt University (US)
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3390/cancers17213472
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health